ABOS vs JNJ · $73.3M cap vs P/E 17, rev $49.37B
Acumen Pharmaceuticals Inc (ABOS) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Acumen Pharmaceuticals Inc (ABOS) is a biotechnology company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
ABOS does not have a complete income-statement cache yet.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
ABOS currently screens at market cap $73.3M. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the ABOS and JNJ stock pages for the full models.
Not investment advice.